ENDPOINTS NEWS17h
Mer­ck and Ei­sai re­veal late-stage fail for Keytru­da and Lenvi­ma in gas­troe­sophageal can­cer
Merck's Keytruda and Eisai's Lenvima combo with chemo failed survival endpoint in gastroesophageal cancer study, but ...
ENDPOINTS NEWS20h
Take­da dis­con­tin­ues US sup­ply of gout drug Uloric over gener­ic com­pe­ti­tion
Takeda has ended the manufacturing and supply of its gout drug Uloric in the US market as more patients turn to generic ...
ENDPOINTS NEWS18h
Up­com­ing PDU­FA dates may be en­snared by Trump's pause at HHS, an­a­lyst says
President Donald Trump's communications pause for HHS, FDA and other health-related agencies could push some drug approval ...
ENDPOINTS NEWS17h
With Sam Alt­man’s help, Retro Bio­sciences eyes $1B to ex­tend lifes­pan by 10 years
Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...
ENDPOINTS NEWS22h
No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al
Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...
ENDPOINTS NEWS22h
Boehringer merges can­cer vac­cine and on­colyt­ic virus teams; Dan­tari sells off as­sets
Boehringer Ingelheim merges AMAL and ViraTherapeutics cancer units, Dantari sells assets to Adanate, Madrona raises $770M, and Abdera adds JJDC and Foresite as investors.